Quality of life changes in COPD patients treated with salmeterol.

Changes in health-related quality of life (HRQoL) were evaluated in patients with chronic obstructive pulmonary disease (COPD) following treatment with placebo, salmeterol 50 microg twice a day or 100 microg twice a day by metered-dose inhaler. Patients completed the disease-specific St. George's Respiratory Questionnaire (SGRQ) and the Medical Outcomes Study Short Form 36 (SF-36) at baseline and after 16 wk of treatment. Data from 283 patients (95 patients in the placebo group and 94 in each salmeterol group) were available for HRQoL analysis. Apart from a small difference in ages, all treatment groups were well matched at baseline in terms of forced expiratory volume in one second (FEV1) and HRQoL scores. Compared with placebo, salmeterol 50 microg twice a day was associated with significant improvements in SGRQ "Total" and "Impacts" scores which exceeded the threshold for a clinically significant change. This was not seen with salmeterol 100 microg twice a day. Changes in SGRQ and SF-36 scores correlated. They also showed a weak but significant relationship with FEV1. This study has shown that a modest change in lung function may be associated with clinically significant gain in health and well-being in COPD patients.

[1]  D. Kellerman,et al.  Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  P. Jones,et al.  Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. , 1995, American journal of respiratory and critical care medicine.

[3]  A. Tosteson,et al.  Changes in dyspnea, health status, and lung function in chronic airway disease. , 1995, American journal of respiratory and critical care medicine.

[4]  T. W. van der Mark,et al.  Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. , 1994, Thorax.

[5]  J. Ware,et al.  Translating health. The International Quality of Life Assessment (IQOLA) project , 1994 .

[6]  P. Jones,et al.  Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. , 1994, The European respiratory journal.

[7]  D. Postma,et al.  Quality-of-life in a long-term multicentre trial in chronic nonspecific lung disease: assessment at baseline. The Dutch CNSLD Study Group. , 1993, The European respiratory journal.

[8]  H. Magnussen,et al.  Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. , 1993, Chest.

[9]  J. Palmer,et al.  Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group. , 1993, Thorax.

[10]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[11]  J. Palmer,et al.  A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. , 1992, The European respiratory journal.

[12]  G. Colice,et al.  Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. , 1992, Chest.

[13]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[14]  F. Sciurba,et al.  Nasal cannula and transtracheal oxygen delivery. A comparison of patient response after 6 months of each technique. , 1992, The American review of respiratory disease.

[15]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[16]  P. Jones,et al.  Influence of demographic and disease related factors on the degree of distress associated with symptoms and restrictions on daily living due to asthma in six countries. , 1991, The European respiratory journal.

[17]  G. Guyatt,et al.  Measuring functional status in chronic lung disease: conclusions from a randomized control trial. , 1989, Respiratory medicine.

[18]  N. Douglas,et al.  Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. , 1990, BMJ.

[19]  P. Jones,et al.  Patients' perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors. , 1990, Clinical science.

[20]  P Littlejohns,et al.  Relationships between general health measured with the sickness impact profile and respiratory symptoms, physiological measures, and mood in patients with chronic airflow limitation. , 1989, The American review of respiratory disease.

[21]  G. Guyatt,et al.  Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.

[22]  M. Bury,et al.  Impairment, disability and handicap in chronic respiratory illness. , 1989, Social science & medicine.

[23]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[24]  H. D. Short,et al.  Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. , 1987, The American review of respiratory disease.

[25]  C. Wells,et al.  Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. , 2015, The American review of respiratory disease.

[26]  A. Morgan,et al.  Effect of attitudes and beliefs on exercise tolerance in chronic bronchitis. , 1983, British medical journal.